Latest news with #Psoriasis
&w=3840&q=100)
Business Standard
13 hours ago
- Business
- Business Standard
Sun Pharma Advanced Research hits 20% lower band; what's rattling Street?
Sun Pharma Advanced Research Company (SPARC) shares slumped 20 per cent in trade on Wednesday, June 4, 2025, hitting its lower circuit at ₹156.5 per share on BSE. The stock was under pressure after the company's partner Sun Pharmaceutical Industries informed that its phase 2 trial for evaluating SOLARES PsO and SOLARES AD studies failed to meet the primary endpoint. In the past one year, Sun Pharma Advanced Research Company shares have declined 3 per cent as compared to Sensex's rise of around 12 per cent. At 9:36 AM, Sun Pharma Advanced Research share price was down 15.16 per cent at ₹165.95 per share on the BSE. In comparison, the BSE Sensex was up 0.04 per cent at 80,766.66. The market capitalisation of the company stood at ₹5,385.44 crore. The 52-week high of the stock was at ₹257.7 per share and the 52-week low of the stock was at ₹109.2 per share. Why did Sun Pharma Advanced Research stock tanked? The company released a filing on Tuesday, after market hours, in which it said that the phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD) failed to meet primary endpoint of 75 per cent improvement in Psoriasis Area and Severity Index (PASI). "SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD). SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16 respectively," the filing read. It added: SPARC and SPIL will evaluate the appropriate next steps for SCD-044. Psoriasis is a chronic autoimmune condition characterised by skin inflammation and accelerated skin cell growth, resulting in raised, scaly patches called plaques, most commonly on the elbows, knees, scalp, and trunk. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterised by dry, itchy, and inflamed skin. It's a long-term condition that can cause patchy rashes and can occur at any age, though it often begins in childhood.
Time of India
13 hours ago
- Business
- Time of India
Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
Shares of Sun Pharma Advanced Research Company (SPARC), a unit of India's largest drug maker Sun Pharmaceutical Industries , tumbled as much as 20% on Wednesday to Rs 156.50 on the BSE after the company disclosed that its investigational drug SCD-044 failed to meet the main goals in late-stage clinical trials for psoriasis and atopic dermatitis. In a filing released post-market hours on Tuesday, SPARC said, 'SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD)." "SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16, respectively,' the company said. The company further added, 'SPARC and SPIL will evaluate the appropriate next steps for SCD-044.' SPARC confirmed that, given the failure to meet primary endpoints, the development of the drug, also known as Vibozilimod, is being discontinued, and no further clinical trials are planned. The setback is significant as the drug was seen as a key asset in the company's speciality pipeline. Also read: Flipkart exits Aditya Birla Fashion and Retail in Rs 582 crore bulk deal; ABFRL stock tumbles 11% Over the past year, SPARC shares have declined about 3%, underperforming the benchmark Sensex, which has risen roughly 12% during the same period. Surprise FDA inspection at Halol unit Separately, CNBC-TV18 reported on Wednesday that a surprise inspection was underway at Sun Pharma's Halol facility, one of its largest manufacturing units, by three inspectors from the U.S. Food and Drug Administration. The Halol unit was last inspected in May 2022 and is currently under an import alert following a warning letter from the regulator. Also read | Sensex will hit 1.5 lakh by 2030 & 3 lakh by 2035! Raamdeo Agrawal makes big prediction About the drug and its target conditions Vibozilimod was being developed as a treatment for psoriasis and atopic dermatitis, two chronic inflammatory skin conditions. Psoriasis is marked by raised, scaly plaques on the skin due to accelerated skin cell growth, often affecting the elbows, knees, scalp, and trunk. Atopic dermatitis, or eczema, typically involves dry, itchy, and inflamed skin, often beginning in childhood but potentially affecting people at any age. The failure of the Phase 2 studies now casts uncertainty over SPARC's speciality drug pipeline, with investors and analysts awaiting further clarity on the company's next steps. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Zawya
3 days ago
- Business
- Zawya
Novartis and Kuwait Society of Dermatologists enter strategic partnership to advance dermatological care in Kuwait
Under the title 'United for Dermatology', the partnership will drive awareness, disease understanding, and improve the lives of patients in Kuwait diagnosed with Psoriasis, Hidradenitis Suppurativa & Chronic Spontaneous Urticaria Kuwait City, Kuwait – Novartis, a global leader in innovative medicines, signed a partnership agreement with the Kuwait Society of Dermatologists, focused on transforming dermatological care in Kuwait. This strategic partnership will prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of bridging diagnostic gaps and improving the quality of life for patients. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. This partnership is focused on increasing education and disease awareness within the public and HCPs, in addition to evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. Dr. Atlal Allafi, President, Kuwait Society of Dermatologists, said, 'Our partnership with Novartis is focused on breaking down barriers to care. Together, we're working to empower patients to recognize symptoms earlier and support physicians in identifying these conditions sooner. By accelerating diagnosis and access to treatment, we aim to enhance patient outcomes and overall well-being.' Rabab Monir, Country Operations Head - Kuwait, Novartis, added, 'Driven by our mission to transform the future of medicine, Novartis is proud to join forces with the Kuwait Society of Dermatologists to elevate dermatological care across Kuwait. Through this collaboration, we're fostering a healthcare environment where early intervention and personalized treatment pave the way for improved patient outcomes.' A professional organization for dermatologists in Kuwait, the Kuwait Society of Dermatologists is dedicated to advancing dermatological care through education, research, and public awareness. Committed to the highest standards of medical ethics and excellence, the society plays a key role in promoting skin health across the nation. Dr Abeer Albazali, Vice President, Kuwait Society of Dermatologists, commented, 'We aim to foster collaboration among dermatologists, encouraging the exchange of knowledge and best practices that drive progress in patient care. This partnership empowers us to move from dialogue to delivery—bringing global breakthroughs to life through locally tailored solutions.' Through this collaboration, Novartis and the Kuwait Society of Dermatologists reinforce their mutual commitment to a future where patients benefit from early diagnosis, individualized care, and an improved quality of life. Disease Descriptors Chronic Spontaneous Urticaria (CSU) is a medical condition that affects 0.5-1 per cent of the global population and is characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition more common in women and often undiagnosed, marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. It is estimated that between 1 and 3 per cent of the population across countries in the Gulf are affected by this condition. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
Yahoo
09-05-2025
- Business
- Yahoo
Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting
First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements in Phase 2a in patients with psoriasis Results further confirm well-tolerated safety profile, with no serious adverse events or discontinuations CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announced the presentation of Phase 2a results in a late-breaking oral presentation with a companion poster at the Society for Investigative Dermatology 2025 Annual Meeting, taking place May 7-10, 2025, in San Diego, California. 'We're highly encouraged by the safety profile observed in our Phase 2a study and the notable impact of our oral Nck modulator AX-158 on key disease biomarkers and clinical severity scores,' said Dr. Rob Armstrong, Chief Executive Officer of Artax Biopharma. 'These results further support the potential of AX-158 to offer a truly novel mechanism to modulate TCR signaling rather than inhibit it, and we're committed to continuing to advance this promising candidate to meet the unmet needs of patients with T cell-mediated autoimmune diseases.' Oral presentation details 'AX-158 Proof-of-Mechanism Safety Study: Evaluating a Novel T cell Receptor (TCR) Signal Modulator in Patients with Mild-to-Moderate Plaque Psoriasis (NCT05725057),' D.S. Batty, C. VanDeusen, S. Garcet, J. Krueger. AX-158 was evaluated in a Phase 2a trial in participants with mild to moderate plaque psoriasis in multiple centers in the UK. Participants were randomized 2:1 to receive a single daily dose of 10mg AX-158 or placebo. A total of 31 participants were treated for 28 days. The primary endpoint of the study was safety, with secondary endpoints to demonstrate proof of mechanism. Key findings include: When administered every day at a 10mg dose, AX-158 was found to be safe and well-tolerated No Grade ≥ 3 treatment-related adverse effects (TEAEs) No discontinuation due to TEAEs No serious or opportunistic infections Longitudinal skin biopsies showed a trend of reduction in the number of CD8+ T cells in patients treated with AX-158 Biomarker analyses revealed statistically significant impacts on IL-17 and IL-12 signalling pathways Statistically significant modulation of multiple psoriasis-related gene sets was observed (MAD3, MAD5, Yao and Gudjonsson*1) At end of study, only patients who received AX-158 achieved PASI50 or greater Dr. Scott Batty, Chief Medical Officer of Artax Biopharma, commented, 'We are deeply grateful to the investigators, their teams, and all the participants who made this progress possible. AX-158 has a unique mechanism of action that modulates TCR signaling to restore tolerance to self while maintaining response against pathogens. We are excited to continue advancing AX-158 and exploring its broad potential across T cell-driven autoimmune diseases, including atopic dermatitis and rheumatoid arthritis.' Dr. James Krueger, Head of Laboratory for Investigative Dermatology at the Rockefeller University and member of the Scientific Advisory Board at Artax Biopharma, added, 'From my blinded analysis of the patient samples in this phase 2a study, it is clear that AX-158 shows a clear impact on T cells and related biomarkers in this patient population.' About Artax Biopharma Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T cell-driven autoimmune diseases. Artax's first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options as both monotherapy and in combination with other treatments. Artax Biopharma is based in the Boston area and raised funding from investors including Advent Life Sciences, Sound Bioventures, The Termeer Family Office, the Fuhrer Family Office and Columbus Venture Partners. For more info, see or follow us on LinkedIn. About Nck modulation We believe there is significant potential for Nck modulation to revolutionize treatment of T cell-driven diseases. Immunomodulation maintains healthy control of the immune system, while addressing the underlying source of T cell-driven diseases. Central to a well-functioning immune system is the T cell receptor (TCR). When TCR signaling becomes dysregulated, it causes T cell-driven conditions, including autoimmune diseases. We believe the immunomodulation mechanism offered by our investigational agents holds broad potential to revolutionize how these T cell-driven autoimmune diseases are addressed, while not impairing the ability of a patient's immune system to function properly. AX-158, our lead Nck modulator, has shown strong, broad cytokine modulation as well as modulation of mixed lymphocyte reactions. Good data on therapeutic efficacy with AX-158 were observed in murine models of self-antigen activation (EAE), with a prolonged pharmacodynamic effect in EAE, suggesting durable immune modulation. AX-158 showed no immunosuppression in models of strong antigen stimulation. Studies with AX-158 showed substantial preclinical evidence of activity in the Th2, Th17, Th1/Th0 pathways, suggesting that applications could be quite broad across the autoimmune space. AX-158 is an investigational therapy that has not been approved by any regulatory authority worldwide, and its safety and efficacy have not yet been established. To obtain a copy of the presentation and for any inquiries, please reach out to contact@ Contacts: Maria Nichol, DPhil, EPA, CPA Chief Business Officer mnichol@ Media: Madelin HawtinLifeSci Communicationsmhawtin@ 1 Tian S, et al. PLoS ONE 7(9): e44274; Yao Y, et al. PLoS ONE 3(7): e2737; Gudjonsson JE, et al. J Invest Dermatol. 2009;129(12):2795–804Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
30-04-2025
- Health
- Zawya
Novartis and Emirates Dermatology Society renew strategic partnership to advance dermatological care in UAE
In an era of rapid medical innovation and information overload, diagnostic accuracy and clinical authenticity are crucial to eliminating delays, preventing misdiagnoses and ultimately enhancing patient outcomes Dubai, UAE – Novartis, a global leader in innovative medicines and the Emirates Dermatology Society (EDS) today announced the renewal of their partnership focused on revolutionizing dermatological care in the United Arab Emirates. Now entering its third year, the collaboration continues to prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of closing diagnostic gaps and improving the quality of life for patients. While dermatology has made tremendous strides in the past few years, there is still an opportunity to accelerate the diagnosis and care for patients across the UAE. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. Chronic Spontaneous Urticaria (CSU) is a medical condition characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. This partnership is focused on addressing these challenges with evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. 'The partnership with Novartis is about proactively addressing the barriers to care. We are committed to helping physicians recognize these conditions earlier, ensuring patients receive timely treatment and improving their overall well-being,' said Dr. Ayman Alnaeem, President, Emirates Dermatology Society. 'At Novartis, our commitment to reimagining medicine drives us to collaborate with organizations like EDS to advance dermatological care in the Gulf region. Together, we are building a healthcare ecosystem where timely, personalized care leads to better patient outcomes,' added Mohamed Ezz Eldin, Head of GCC, Novartis. The Emirates Dermatology Society (EDS) is not just a professional network—it is a leading force in shaping the future of dermatological care in the UAE. With an active management committee overseeing its activities, EDS plays a crucial role in connecting dermatologists, facilitating knowledge-sharing and promoting excellence in dermatology 'Our goal is to bring dermatologists together to collaborate, share insights and contribute to the ongoing evolution of care. This partnership allows us to turn discussions into action—translating global innovations into local solutions,' commented, Dr Raghda Al Maashari, Cultural Committee Chairperson, Emirates Dermatology Society. With this partnership, Novartis and EDS reaffirm their shared vision: a future where every patient has access to timely diagnosis, personalized treatment and a better quality of life. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
